{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:23:14Z","timestamp":1785158594669,"version":"3.55.0"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jconrel.2023.01.083","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T01:44:31Z","timestamp":1675907071000},"page":"292-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies"],"prefix":"10.1016","volume":"355","author":[{"given":"Sachin S.","family":"Gaikwad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal R.","family":"Pathare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur A.","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita A.","family":"Waykhinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh D.","family":"Laddha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor S.","family":"Salunkhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay J.","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi S.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep H.","family":"Ramteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.01.083_bb0005","series-title":"Chronic obstructive pulmonary disease (COPD)","year":"2023"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0010","series-title":"Asthma","year":"2023"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"14","key":"10.1016\/j.jconrel.2023.01.083_bb0020","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2165\/00003495-200565140-00005","article-title":"Budesonide inhalation suspension for the treatment of asthma in infants and children","volume":"65","author":"Berger","year":"2005","journal-title":"Drugs."},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.083_bb0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/00325481.2017.1308208","article-title":"Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma","volume":"129","author":"Brunton","year":"2017","journal-title":"Postgrad. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.083_bb0030","article-title":"Intravenous magnesium sulfate for treating children with acute asthma in the emergency department","volume":"129","author":"Griffiths","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0035","doi-asserted-by":"crossref","first-page":"106045","DOI":"10.1016\/j.rmed.2020.106045","article-title":"Use of corticosteroids in asthma and COPD patients with or without COVID-19","volume":"170","author":"Hasan","year":"2020","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ptr.5761","article-title":"Nigella sativa supplementation improves asthma control and biomarkers: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Koshak","year":"2017","journal-title":"Phytother. Res."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0045","doi-asserted-by":"crossref","first-page":"106259","DOI":"10.1016\/j.ejps.2022.106259","article-title":"Functionalized FcRn-targeted nanosystems for oral drug delivery: a new approach to colorectal cancer treatment","volume":"176","author":"Hameedat","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0050","series-title":"M5 PCN137 Cost comparison of adverse events and treatment administration of lurbinectedin versus intravenous topotecan for relapsed small cell lung cancer in Spain and the united kingdom Pharmamar","author":"Garc\u00eda","year":"2023"},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32423-0","article-title":"Intranasal administration of resveratrol successfully prevents lung cancer in A\/J mice","volume":"8","author":"Monteillier","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0060","first-page":"468","article-title":"Efficacy of povidone-iodine nasal and oral antiseptic preparations against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)","volume":"100","author":"Pelletier","year":"2021","journal-title":"Ear Nose Throat J."},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.083_bb0065","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1378\/chest.07-0208","article-title":"Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study","volume":"132","author":"de Jong","year":"2007","journal-title":"Chest."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0070","first-page":"135","article-title":"Oral theophylline for chronic obstructive pulmonary disease","volume":"99","author":"Ram","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0075","doi-asserted-by":"crossref","first-page":"102087","DOI":"10.1016\/j.parint.2020.102087","article-title":"Strongyloides stercoralis hyperinfection syndrome presenting as mechanical ileus after short-course oral steroids for chronic obstructive pulmonary disease (COPD) exacerbation","volume":"76","author":"Rothe","year":"2021","journal-title":"Parasitol. Int."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1179\/joc.2009.21.1.101","article-title":"Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy","volume":"21","author":"Braccini","year":"2009","journal-title":"J. Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2023.01.083_bb0085","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial","volume":"8","author":"Jones","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1479-5876-11-106","article-title":"Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer","volume":"11","author":"Weibel","year":"2013","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0095","first-page":"1287","article-title":"Oral rivaroxaban for the treatment of symptomatic Pulmonary embolism","volume":"28","author":"Bailey","year":"2012","journal-title":"Cardiol. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0100","first-page":"20","article-title":"The history of therapeutic aerosols","volume":"30","author":"Stephen","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3132\/pcrj.2007.00017","article-title":"Erratum to 'Inhalation therapy: an historical review'","volume":"16","author":"Sanders","year":"2007","journal-title":"Prim. Care Respir J."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpb.2020.02.013","article-title":"3D characterisation of dry powder inhaler formulations: developing X-ray micro computed tomography approaches","volume":"151","author":"Gajjar","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0115","first-page":"499","article-title":"Dry powder inhalation, part 1: ancient history and precursors to modern dry powder inhalers","volume":"19","author":"Boer","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0120","first-page":"1","article-title":"Dry powder for pulmonary delivery: a comprehensive review","volume":"13","author":"Chaurasiya","year":"2021","journal-title":"Pharmaceutics."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/pharmaceutics13020189","article-title":"Flow and particle modelling of dry powder inhalers: methodologies, recent development and emerging applications","volume":"13","author":"Zheng","year":"2021","journal-title":"Pharmaceutics."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/jamp.2011.0916","article-title":"Aerosol deposition in health and disease","volume":"25","author":"Darquenne","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14356\/kona.2010005","article-title":"Surface analytical techniques in solid-state particle characterization for predicting performance in dry powder inhalers","volume":"28","author":"Wu","year":"2010","journal-title":"Kona Powder Part. J."},{"issue":"13","key":"10.1016\/j.jconrel.2023.01.083_bb0140","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2146\/ajhp100452","article-title":"Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease","volume":"68","author":"Barrons","year":"2011","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0145","first-page":"34","article-title":"Dry powder inhalers an overview","volume":"1","author":"Muthumanickam","year":"2010","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0150","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1574885514666190104114209","article-title":"Formulation of dry powder inhaler of antituberculous drugs using spray drying technique and optimization using 23 level factorial design approach","volume":"14","author":"Thakkar","year":"2019","journal-title":"Curr. Drug Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.083_bb0155","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/10717544.2013.868555","article-title":"Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery","volume":"21","author":"Rattanupatam","year":"2014","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.083_bb0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/13543776.18.4.429","article-title":"Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins","volume":"18","author":"Onoue","year":"2008","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0165","series-title":"Conference Proceedings Dry Powder Inhalers: An Overview Introduction Powder Inhalers Today Unit-Dose Devices Multi-Dose Devices Factors that Impact Performance and Patient Acceptance DPI Development Future DPI Developments Summary","author":"Atkins","year":"2005"},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0170","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.4103\/ijrc.ijrc_57_19","article-title":"Dry powder inhalers: particle size and patient-satisfaction","volume":"10","author":"Jindal","year":"2021","journal-title":"Indian J. Respir. Care"},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000029329","article-title":"Pulmonary defence mechanisms","volume":"66","author":"Nicod","year":"1999","journal-title":"Respiration."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0180","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/17425255.2016.1209485","article-title":"Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClickTM dry-powder inhaler in the treatment of asthma","volume":"12","author":"Welch","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"10","key":"10.1016\/j.jconrel.2023.01.083_bb0185","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s12325-019-01066-6","article-title":"Understanding dry powder inhalers: key technical and patient preference attributes","volume":"36","author":"Will","year":"2019","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2023.01.083_bb0190","first-page":"1","article-title":"A critical review on emerging trends in dry powder inhaler formulation for the treatment of pulmonary aspergillosis","volume":"132","author":"Cheng","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0195","doi-asserted-by":"crossref","first-page":"121457","DOI":"10.1016\/j.ijpharm.2022.121457","article-title":"The future of dry powder inhaled therapy: promising or discouraging for systemic disorders?","volume":"614","author":"Ye","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0200","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.2042-7158.2012.01525.x","article-title":"Rational design of a dry powder inhaler: device design and optimisation","volume":"64","author":"Friebel","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.01.083_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.04.044","article-title":"Dry powder inhalers (DPIs) A review of device reliability and innovation","volume":"360","author":"Islam","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0210","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/pharmaceutics14030500","article-title":"Experimental evaluation of dry powder inhalers during inhalation and exhalation using a model of the human respiratory system (xPULMTM)","volume":"14","author":"Pasteka","year":"2022","journal-title":"Pharmaceutics."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.01.083_bb0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijpharm.2012.04.019","article-title":"The development of a new dry powder inhaler","volume":"431","author":"Zhang","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0220","series-title":"Medicinal Aerosols, 1st edition, Particulate Interactions in Dry Powder Formulations for Inhalation","first-page":"133","author":"Ming Zeng","year":"2023"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0225","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40261-021-01021-w","article-title":"Performance characteristics of Breezhaler\u00ae and Aerolizer\u00ae in the real-world setting","volume":"41","author":"Molimard","year":"2021","journal-title":"Clin. Drug Investig."},{"issue":"11","key":"10.1016\/j.jconrel.2023.01.083_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2015.09.013","article-title":"New developments in inhaler devices within pharmaceutical companies: a systematic review of the impact on clinical outcomes and patient preferences","volume":"109","author":"Ninane","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0235","first-page":"100096","article-title":"The use of heat to deliver fentanyl via pulmonary drug delivery","volume":"3","author":"Vazda","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/187221107779814159","article-title":"Development of dry powder inhalers","volume":"1","author":"Chougule","year":"2007","journal-title":"Rec. Pat Drug Deliv. Formul."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/17425247.2020.1702643","article-title":"Physical stability of dry powder inhaler formulations","volume":"17","author":"Shetty","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4155\/tde-2020-0091","article-title":"Dry powder inhalers: a concise summary of the electronic monitoring devices","volume":"12","author":"Mehta","year":"2021","journal-title":"Ther. Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0255","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/jamp.2015.1220","article-title":"Effect of flow rate on in vitro aerodynamic performance of NEXThaler\u00ae in comparison with Diskus\u00ae and Turbohaler\u00ae dry powder inhalers","volume":"29","author":"Buttini","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0260","first-page":"11","article-title":"The Diskus\u2122: a review of its position among dry powder inhaler devices","volume":"1","author":"Chrystn","year":"2007","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0265","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1461-5347(98)00099-6","article-title":"Dry powder formulations for pulmonary delivery","volume":"1","author":"Malcolmson","year":"1998","journal-title":"Pharm. Sci. Technol."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0270","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/03639040802235902","article-title":"Advancements in dry powder delivery to the lung","volume":"34","author":"Son","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0275","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2332\/allergolint.11-OA-0332","article-title":"In vitro evaluation of dry powder inhaler devices of corticosteroid preparations","volume":"61","author":"Tamura","year":"2012","journal-title":"Allergol. Int."},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.083_bb0280","first-page":"247","article-title":"State of the art and new perspectives on dry powder inhalers","volume":"3","author":"Terzano","year":"1999","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2023.01.083_bb0285","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1461-5347(00)00275-3","article-title":"Latest advances in the development of dry powder inhalers","volume":"3","author":"Ashurst","year":"2000","journal-title":"Pharm. Sci. Technol. Today"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0290","doi-asserted-by":"crossref","unstructured":"S.P. Sellers, G.S. Clark, R. E. Sievers, J. F. Carpenter. Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO 2-assisted aerosolization, J. Pharm. Sci. 90 (6) 785\u201397. doi:https:\/\/doi.org\/10.1002\/jps.1032.","DOI":"10.1002\/jps.1032"},{"issue":"8","key":"10.1016\/j.jconrel.2023.01.083_bb0295","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1021\/js9700661","article-title":"Pharmaceutical processing with supercritical carbon dioxide","volume":"86","author":"Subramaniam","year":"1997","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0300","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/pharmaceutics10030131","article-title":"Drying technologies for the stability and bioavailability of biopharmaceuticals","volume":"10","author":"Emami","year":"2018","journal-title":"Pharmaceutics"},{"issue":"9\u201310","key":"10.1016\/j.jconrel.2023.01.083_bb0305","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.addr.2006.07.010","article-title":"Particle engineering techniques for inhaled biopharmaceuticals","volume":"58","author":"Shoyele","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.01.083_bb0310","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0378-5173(02)00261-2","article-title":"Rifampicin microparticles production by supercritical antisolvent precipitation","volume":"243","author":"Reverchon","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0896-8446(98)00129-6","article-title":"Supercritical antisolvent precipitation of micro-and nanoparticles","volume":"15","author":"Reverchon","year":"1999","journal-title":"J. Supercrit. Fluids"},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1773-2247(05)50036-4","article-title":"Effect of physical properties of carrier particles on drug emission from a dry powder inhaler device","volume":"15","author":"Murakoshi","year":"1999","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0325","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-006-9174-3","article-title":"Particle engineering for pulmonary drug delivery","volume":"24","author":"Chow","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0330","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","article-title":"Pharmaceutical particle engineering via spray drying","volume":"5","author":"Vehring","year":"2008","journal-title":"Pharm. Res."},{"issue":"7","key":"10.1016\/j.jconrel.2023.01.083_bb0335","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/pharmaceutics13071077","article-title":"Inhalation delivery for the treatment and prevention of covid-19 infection","volume":"1","author":"Eedara","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0340","doi-asserted-by":"crossref","first-page":"578970","DOI":"10.3389\/fphar.2020.578970","article-title":"Indian medicinal plants and formulations and their potential against COVID-19\u2013preclinical and clinical research","volume":"11","author":"Ahmad","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246803","article-title":"Development and evaluation of inhalable composite niclosamide-lysozyme particles: a broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae","volume":"16","author":"Brunaugh","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jconrel.2023.01.083_bb0350","doi-asserted-by":"crossref","DOI":"10.1089\/jamp.2021.0059","article-title":"Preparation and characterization of inhalable ivermectin powders as a potential COVID-19 therapy","volume":"35","author":"Albariqi","year":"2022","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0355","doi-asserted-by":"crossref","first-page":"121122","DOI":"10.1016\/j.ijpharm.2021.121122","article-title":"Inhaled edoxaban dry powder inhaler formulations: development, characterization and their effects on the coagulopathy associated with COVID-19 infection","volume":"608","author":"Rashid","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0360","article-title":"Chronic obstructive pulmonary disease and the COVID-19 pandemic: reciprocal challenges","volume":"78100764","author":"Desl\u00e9e","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0365","doi-asserted-by":"crossref","first-page":"102430","DOI":"10.1016\/j.jddst.2021.102430","article-title":"The pulmonary route as a way to drug repositioning in COVID19 therapy","volume":"63","author":"Sarcinelli","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"10","key":"10.1016\/j.jconrel.2023.01.083_bb0370","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/j.xphs.2022.06.004","article-title":"Antivirals and the potential benefits of orally inhaled drug administration in COVID-19 treatment","volume":"111","author":"Sahin","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0375","first-page":"108004","article-title":"Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: a preclinical tolerance study","volume":"99","author":"Mansour","year":"2021","journal-title":"Int. Immun. Pharmacol."},{"issue":"10","key":"10.1016\/j.jconrel.2023.01.083_bb0380","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jiph.2020.07.004","article-title":"An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics","volume":"13","author":"Wang","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0410","author":"Dry Powder Inhaler Market"},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0415","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3390\/pharmaceutics13091455","article-title":"Dry powder inhalers in the digitalization era: current status and future perspectives","volume":"13","author":"Xiroudaki","year":"2021","journal-title":"Pharmaceutics."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0420","first-page":"948","article-title":"Advancement in dry powder inhaler drug development and industrial pharmacy","volume":"34","author":"Yoen","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0425","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/a-0649-0814","article-title":"Development of a carrier free dry powder inhalation formulation of Ketotifen for pulmonary drug delivery","volume":"70","author":"Azari","year":"2020","journal-title":"Drug Res."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.01.083_bb0430","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpharm.2018.07.065","article-title":"Carrier free indomethacin microparticles for dry powder inhalation","volume":"549","author":"Ceschan","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0435","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1002\/jps.23197","article-title":"Development of budesonide nanocluster dry powder aerosols: preformulation","volume":"101","author":"El-Gendy","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0440","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejps.2004.06.005","article-title":"The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix","volume":"23","author":"Zijlstra","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0445","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1208\/s12249-007-9024-6","article-title":"Development of spray dried liposomal dry powder inhaler of dapsone","volume":"9","author":"Chougule","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"10.1016\/j.jconrel.2023.01.083_bb0450","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1080\/03639045.2019.1609494","article-title":"Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis","volume":"45","author":"Momin","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0455","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s13346-018-0586-5","article-title":"Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil","volume":"9","author":"Nguyen","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2023.01.083_bb0460","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-019-1409-9","article-title":"Effect of USP induction ports, glass sampling apparatus, and inhaler device resistance on aerodynamic patterns of fluticasone propionate\u2013loaded engineered mannitol microparticles","volume":"20","author":"Mehta","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0465","doi-asserted-by":"crossref","first-page":"102356","DOI":"10.1016\/j.jddst.2021.102356","article-title":"Formulation and evaluation of inhalable microparticles of Rizatriptan Benzoate processed by spray freeze-drying","volume":"62","author":"Shokouh","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0470","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.supflu.2012.07.013","article-title":"The effect of lactose micro-spherical crystals prepared by conditioning with supercritical fluid on salbutamol sulphate inhalation performance","author":"Muhammad","year":"2012","journal-title":"J. Supercrit. Fluids"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0475","series-title":"LLP 1700 Diagonal Road Suite. 300 ALEXANDRIA, VA 22314 (US) US 2006\/0254583 A1","author":"Deboeck","year":"2006"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0480","series-title":"Nottingham (GB) Brintech International Limited, Nottinghamshire (GB) US 8,201,555 B2","author":"Chawla","year":"2012"},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0485","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","article-title":"Insights into direct nose to brain delivery: current status and future perspective","volume":"21","author":"Mittal","year":"2014","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.083_bb0490","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/pharmaceutics13060795","article-title":"A dry powder platform for nose-to-brain delivery of dexamethasone: formulation development and nasal deposition studies","volume":"13","author":"Nodilo","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0495","first-page":"213","article-title":"Formulation and device design to increase nose to brain drug delivery system","volume":"35","author":"Deshmukh","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.083_bb0500","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425247.2018.1429401","article-title":"Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery","volume":"15","author":"Battaglia","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0505","doi-asserted-by":"crossref","first-page":"122038","DOI":"10.1016\/j.ijpharm.2022.122038","article-title":"Tailoring functional spray-dried powder platform for efficient donepezil nose-to-brain delivery","volume":"624","author":"Perku\u0161i\u0107","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/10611860601029496","article-title":"Nose-to-brain delivery of TS-002, prostaglandin D2 analogue","volume":"15","author":"Yamada","year":"2007","journal-title":"J. Drug Target."},{"issue":"8","key":"10.1016\/j.jconrel.2023.01.083_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183130","article-title":"Prerequisites for a dry powder inhaler for children with cystic fibrosis","volume":"12","author":"Lexmond","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0520","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4081\/mrm.2017.236","article-title":"Recent advances in capsule-based dry powder inhaler technology","volume":"12","author":"Lavorini","year":"2017","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0525","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejpb.2022.08.006","article-title":"Usability of administration devices for oral and respiratory medicines: views from a UK primary school","volume":"178","author":"Alessandrini","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"72","key":"10.1016\/j.jconrel.2023.01.083_bb0530","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.322.7286.577","article-title":"Comparison of elderly people\u2019s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial","volume":"322","author":"Diggory","year":"2001","journal-title":"BMJ."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0535","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1183\/09031936.00024807","article-title":"Inspiratory flow rates at different levels of resistance in elderly COPD patients","volume":"31","author":"Janssens","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.jconrel.2023.01.083_bb0540","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/17425247.2020.1813105","article-title":"Overcoming challenges for development of amorphous powders for inhalation","volume":"17","author":"Chang","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"issue":"10","key":"10.1016\/j.jconrel.2023.01.083_bb0545","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1002\/jps.24574","article-title":"Formulation design of dry powders for inhalation","volume":"104","author":"Weers","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0550","doi-asserted-by":"crossref","first-page":"121758","DOI":"10.1016\/j.ijpharm.2022.121758","article-title":"Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles","volume":"621","author":"Xu","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.083_bb0555","first-page":"1209","article-title":"Dry powder inhaler formulation","volume":"50","author":"Telko","year":"2014","journal-title":"Respir. Care"},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.083_bb0560","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.xphs.2021.09.004","article-title":"Effect of lipidic excipients on the particle properties and aerosol performance of high drug load spray dried particles for inhalation","volume":"111","author":"Shettya","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.01.083_bb0565","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2013.01.003","article-title":"Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance","volume":"443","author":"Son","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.083_bb0570","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/10837450.2017.1342656","article-title":"Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device","volume":"23","author":"Kim","year":"2018","journal-title":"Pharm. Dev. Technol."},{"issue":"5","key":"10.1016\/j.jconrel.2023.01.083_bb0575","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/rmed.2001.1276","article-title":"Evolution of dry powder inhaler design, formulation, and performance","volume":"96","author":"Newman","year":"2002","journal-title":"Respir. Med."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2022.862336","article-title":"Formulation of dry powders for inhalation comprising high doses of a poorly soluble hydrophobic drug","volume":"2","author":"Tarara","year":"2022","journal-title":"Front. Drug Deliv."},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.083_bb0585","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.apsb.2016.03.011","article-title":"Influence of physical properties of carrier on the performance of dry powder inhalers","volume":"6","author":"Peng","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"issue":"21","key":"10.1016\/j.jconrel.2023.01.083_bb0590","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.2174\/138161210791920423","article-title":"Effect of particle formulation on dry powder inhalation efficiency","volume":"16","author":"Hassan","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"27","key":"10.1016\/j.jconrel.2023.01.083_bb0595","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.2174\/1381612821666150820111134","article-title":"Powder production and particle engineering for dry powder inhaler formulations","volume":"21","author":"Lin","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0600","doi-asserted-by":"crossref","unstructured":"S. He, J. Gui, K. Xiong, M. Chen, H. Gao, Y. Fu, A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases, Journal of Nanobiotechnology. 20 (101) (2022) 1-22, doi.org\/10.1186\/s12951-022-01307-x.","DOI":"10.1186\/s12951-022-01307-x"},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0605","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejpb.2014.03.009","article-title":"Spray freeze drying for dry powder inhalation of nanoparticles","volume":"87","author":"Ali","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0610","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4155\/tde-2019-0018","article-title":"Dry powder inhalation of siRNA","volume":"10","author":"Keil","year":"2019","journal-title":"Ther. Del Fut Med."},{"issue":"12","key":"10.1016\/j.jconrel.2023.01.083_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12121196","article-title":"Novel approaches for the treatment of pulmonary tuberculosis","volume":"12","author":"Tan","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0620","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1533\/9780857092205.395","article-title":"Liposome-based carrier systems and devices used for pulmonary drug delivery","author":"Khan","year":"2013","journal-title":"Biomater. Med. Tribol. Res. Dev. Northumbria Univ. Newcastle"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0625","series-title":"Targeting Chronic Inflammatory Lung Diseases Using Adv. Drug Deliv. Rev","first-page":"57","article-title":"Novel drug delivery systems and significance in respiratory diseases","author":"Mishra","year":"2020"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0630","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s13346-021-01102-5","article-title":"Development of a novel rapamycin loaded nano-into micro-formulation for treatment of lung inflammation","volume":"12","author":"Craparo","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0635","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s13346-019-00690-7","article-title":"Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases","volume":"10","author":"Pulivendala","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0640","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.chest.2019.11.036","article-title":"Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases","volume":"157","author":"Wang","year":"2020","journal-title":"Chest."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0645","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jconrel.2011.12.004","article-title":"Controlled pulmonary drug and gene delivery using polymeric nano-carriers","volume":"161","author":"Beck-Broichsitter","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0650","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/pharmaceutics14050895","article-title":"Dry powder formulation of simvastatin nanoparticles for potential application in pulmonary arterial hypertension","volume":"14","author":"Zendehdel Baher","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0655","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s12551-017-0319-x","article-title":"New perspectives in nanotherapeutics for chronic respiratory diseases","volume":"9","author":"Da Silva","year":"2017","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0660","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/092986710790416290","article-title":"Development of nanoparticles for antimicrobial drug delivery","volume":"17","author":"Zhang","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0665","first-page":"97","article-title":"Nanoparticle interaction with the immune system\/Interakcije nanodelcev z imunskimsistemom","volume":"66","author":"Kononenko","year":"2015","journal-title":"Arch. Ind. Hyg. Toxicol."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0670","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0675","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1016\/j.apt.2018.08.011","article-title":"Nicotine-loaded chitosan nanoparticles for dry powder inhaler (DPI) formulations impact of nanoparticle surface charge on powder aerosolization","volume":"29","author":"Hui Wanga","year":"2018","journal-title":"Adv. Powder Technol."},{"issue":"406","key":"10.1016\/j.jconrel.2023.01.083_bb0680","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fbioe.2019.00406","article-title":"Nanomedicine approaches for the pulmonary treatment of cystic fibrosis","volume":"7","author":"Velino","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0685","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1073\/pnas.182233999","article-title":"Trojan particles: large porous carriers of nanoparticles for drug delivery","volume":"99","author":"Tsapis","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0690","first-page":"10074","article-title":"Supercritical CO2-assisted spray drying of strawberry-like gold-coated magnetite nanocomposites in chitosan powders for inhalation","volume":"10","author":"Silva","year":"2023","journal-title":"Materials"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0695","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.colsurfb.2015.12.017","article-title":"Disintegration of nano-embedded microparticles after deposition on mucus: a mechanistic study","volume":"139","author":"Ruge","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0700","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejpb.2010.12.002","article-title":"Surfactant free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation","volume":"78","author":"Lebhardt","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0705","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejps.2005.04.009","article-title":"Microencapsulated chitosan nanoparticles for lung protein delivery","volume":"25","author":"Grenha","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0710","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijpharm.2003.09.041","article-title":"Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung","volume":"269","author":"Sham","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0715","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejpb.2015.03.010","article-title":"Macrophage uptake of cylindrical microparticles investigated with correlative microscopy","volume":"95","author":"Tscheka","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0720","first-page":"91","article-title":"Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Chennakesavulu","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0725","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2022.973599","article-title":"Optimizing the design and dosing of dry powder inhaler formulations of the cationic liposome adjuvant CAF\u00ae01 for pulmonary immunization","volume":"2","author":"Thakur","year":"2022","journal-title":"Front. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0730","series-title":"Proceedings of International Conference on Drug Discovery (ICDD)","article-title":"Dry powder inhaler of a cytotoxic agent, a new avenue as drug delivery for the lung cancer","author":"Prachi","year":"2020"},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.083_bb0735","first-page":"709","article-title":"Fluticasone propionate liposomes for pulmonary delivery","volume":"71","author":"Nirale","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0740","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ijpharm.2015.10.020","article-title":"Inhalable liposomal dry powder of gemcitabine HCl: formulation, in vitro characterization and in vivo studies","volume":"496","author":"Gandhi","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.083_bb0745","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10717540490467375","article-title":"Development of liposomal amphotericin B dry powder InhalerFormulation","volume":"11","author":"Shah","year":"2004","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0750","first-page":"45","article-title":"Preparation, statistical optimization and in-vitro characterization of a dry powder inhaler (DPI) containing solid lipid nanoparticles encapsulating amphotericin b: ion paired complexes with distearoyl phosphatidylglycerol","volume":"19","author":"Mehrabani Yeganeh","year":"2020","journal-title":"Iran J. Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.083_bb0755","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-019-1334-y","article-title":"Ethambutol-loaded solid lipid nanoparticles as dry powder inhalable formulation for tuberculosis therapy","volume":"20","author":"Nemati","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0760","first-page":"4828169","article-title":"Preparation of curcumin solid lipid nanoparticles loaded with flower-shaped lactose for lung inhalation and preliminary evaluation of cytotoxicity in vitro","author":"Nan","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0765","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1166\/jbn.2009.036","article-title":"Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery","volume":"5","author":"Bi","year":"2009","journal-title":"J Biomed. Nano technol."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0770","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/mp100255c","article-title":"Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine","volume":"8","author":"Thomas","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0775","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s11095-009-9894-2","article-title":"Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery","volume":"26","author":"Sung","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0780","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41565-018-0358-x","article-title":"Self-assembled peptide\u2013poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis","volume":"14","author":"Guan","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0785","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejpb.2018.07.025","article-title":"Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions","volume":"131","author":"Ernst","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0790","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.nano.2012.04.005","article-title":"Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study","volume":"9","author":"Sinha","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0795","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jconrel.2015.07.024","article-title":"Nanotechnology approaches for inhalation treatment of lung diseases","volume":"219","author":"Kuzmov","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0800","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2009.11.033","article-title":"Liposomes as delivery systems for antibiotics","volume":"387","author":"Drulis-Kawa","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0805","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijpharm.2008.02.011","article-title":"Inhaled nanoparticles-a current review","volume":"356","author":"Yang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0810","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art","volume":"86","author":"Weber","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0815","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.3390\/ijms15045852","article-title":"Nanoparticle-mediated pulmonary drug delivery: a review","volume":"15","author":"Paranjpe","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0820","doi-asserted-by":"crossref","DOI":"10.1208\/aapsj070104","article-title":"Carrier-based strategies for targeting protein and peptide drugs to the lungs","volume":"7","author":"Cryan","year":"2005","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0825","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.apt.2019.10.013","article-title":"A particle technology approach toward designing dry-powder inhaler formulations for personalized medicine in respiratory diseases","volume":"31","author":"Kadota","year":"2020","journal-title":"Adv. Powder Technol."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0830","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.2147\/IJN.S91631","article-title":"Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration","volume":"10","author":"Abdelbary","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.01.083_bb0835","doi-asserted-by":"crossref","unstructured":"A.H. de Boera, P. Hagedoorna, M. Hoppentochta, F. Buttinib, F. Grasmeijeraand H.W. Frijlink, Dry powder inhalation: past, present and future, Expert Opin. Drug Deliv. 14 (4) (2017) 499 - 512, doi.org\/10.1080\/17425247.2016.1224846.","DOI":"10.1080\/17425247.2016.1224846"},{"issue":"14","key":"10.1016\/j.jconrel.2023.01.083_bb0840","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/07373937.2011.592960","article-title":"Application of design of experiments and multilayer perceptron neural network in optimization of the spray-drying process","volume":"29","author":"Mihajlovic","year":"2011","journal-title":"Dry. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.083_bb0845","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.xphs.2016.10.002","article-title":"Predicting the fine particle fraction of dry powder inhalers using artificial neural networks","volume":"106","author":"Muddle","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.01.083_bb0850","doi-asserted-by":"crossref","first-page":"107367","DOI":"10.1016\/j.compchemeng.2021.107367","article-title":"Machine learning approach for carrier surface design in carrier-based dry powder inhalation","volume":"151","author":"Farizhandi","year":"2021","journal-title":"Comput. Chem. Eng."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:40:44Z","timestamp":1759164044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923000925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":165,"alternative-id":["S0168365923000925"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.083","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}